Home Online Features Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study
Press Releases
Palatin Technologies, Inc.  
March 31, 2025

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

Primary endpoint met in the 8-week treatment study (highly statistically significant).Co-administered group had a 4.4% reduction in weight compared to 1.6% for the placebo group (p<0.0001).Primary analysis for the co-administered

avatar profile Olean Times Herald

Olean Times Herald

email Olean Times Herald

Local & Social